Participation in Solutions Studio creates a structured route to integration in care delivery environments and access to Mayo Clinic Platform’s provider network.

PALO ALTO, CA, UNITED STATES, August 24, 2026 /EINPresswire.com/ -- PGxAI, an AI-native precision medicine company focused on personalized prescribing and drug-metabolism intelligence, today announced that Andromeda, its first-in-class decision-support tool, is now a qualified solution on Mayo Clinic Platform. PGxAI, through a clinician-reviewable architecture, brings together pharmacogenomics and other multi-omics data, phenoconversion-related factors, drug-drug and drug-condition interactions, clinical context, and real-world evidence in a unified decision layer for medication guidance.

PGxAI is designed to support therapy selection, dosing, medication safety, and outcomes optimization for health systems, payers, laboratories, and biopharma. The solution embeds directly into prescribing workflows within EHRs, helping care teams move from complex biological and clinical signals to actionable, auditable medication decisions. Through Mayo Clinic Platform, PGxAI gains a structured path toward deployment readiness, provider-led evaluation, and clinical workflow integration planning.

“Our goal is to make the right medication and dose the starting point of treatment, rather than the result of months of trial and error. Andromeda makes personalized prescribing practical in everyday clinical care—with transparent reasoning, verifiable sources, and the final decision remaining with the clinician,” said Mike Zack, M.D., Ph.D., MPH, CEO and Co-Founder, PGxAI.

Mayo Clinic Platform supports digital health solutions developers with the infrastructure and ecosystem needed to bring digital solutions into real-world clinical and administrative workflows. The program evaluates each solution for intended use, proposed value, and clinical and algorithmic performance, providing transparency and credibility, and enabling the adoption of transformative health technologies.

"Qualified solutions are supported by Mayo Clinic Platform’s unique ecosystem and technical infrastructure, enabling expedited validation and potential deployment into clinical and administrative systems,” says Steve Bethke, vice president of Growth & Management at Mayo Clinic Platform.



Media Contact:
Josh Cobb, Jefferson Communications, josh.cobb@jeffersoncommunications.co.uk, +44 2072568912

About PGxAI
PGxAI is an AI-native precision medicine platform focused on personalized prescribing and human drug-metabolism intelligence. The company develops clinician-reviewable software solutions that help health systems, laboratories, and payors use pharmacogenomic, medication, and clinical data for safer therapy selection and dosing. For biopharma, PGxAI applies the same analytical capabilities to patient stratification, evidence generation, and drug development strategy.

Founded by Mike Zack, MD, PhD, MPH—a precision medicine scientist ranked among the world’s top 1% by citations (Elsevier 2026)—and Allan Gobbs, a life sciences entrepreneur with nine exits including five IPOs, PGxAI collaborates with leading partners such as Google Cloud, Microsoft, Nvidia, AWS, InterSystems, MIT (MIMIC-IV), NIH (All of Us), The University of Texas MD Anderson Cancer Center, University of Houston College of Pharmacy, the University of British Columbia, and the Kingdom of Saudi Arabia.

Its Advisory Board includes global leaders in precision medicine, including Russ Altman (Stanford University), John Quackenbush (Harvard T.H. Chan School of Public Health & Dana-Farber Cancer Institute), Bruce Broussard (former CEO, Humana), Roni Zeiger (former Head of Health Strategy at Meta and Chief Health Strategist at Google), and David Blumenthal (former U.S. National Coordinator for Health IT and former President of The Commonwealth Fund), alongside senior affiliates from Thermo Fisher, Quest Diagnostics, and Abbott.

Mayo Clinic does not endorse or warrant the third-party products or services made available through Mayo Clinic Platform, including their functionality, quality, or performance. Mayo Clinic expressly disclaims any express or implied warranties on such third-party products or services, including any implied warranties of merchantability, quality, accuracy, fitness for a particular purpose, or noninfringement. All use of these third-party products or services, including applicable rights or remedies, are governed by separate terms with the applicable third-party developers or providers.

Josh Cobb
Jefferson Communications
+44 20 7256 8912
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.